Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 145

1.

Survey to estimate the prevalence of type 2 diabetes mellitus in hospital patients in Germany by systematic HbA1c measurement upon admission.

Müller-Wieland D, Merkel M, Hamann A, Siegel E, Ottillinger B, Woker R, Fresenius K.

Int J Clin Pract. 2018 Oct 8:e13273. doi: 10.1111/ijcp.13273. [Epub ahead of print]

PMID:
30295392
2.

Insulin Resistance and Vulnerability to Cardiac Ischemia.

Jelenik T, Flögel U, Álvarez-Hernández E, Scheiber D, Zweck E, Ding Z, Rothe M, Mastrototaro L, Kohlhaas V, Kotzka J, Knebel B, Müller-Wieland D, Moellendorf S, Gödecke A, Kelm M, Westenfeld R, Roden M, Szendroedi J.

Diabetes. 2018 Sep 26. pii: db180449. doi: 10.2337/db18-0449. [Epub ahead of print]

PMID:
30257974
3.

Correction: Higher HbA1c Measurement Quality Standards are Needed for Follow-Up and Diagnosis: Experience and Analyses from Germany.

Heinemann L, Kaiser P, Freckmann G, Grote-Koska D, Kerner W, Landgraf R, Merker L, Müller UA, Müller-Wieland D, Roth J, Spannagl M, Wallaschofski H, Nauck M.

Horm Metab Res. 2018 Oct;50(10):e5. doi: 10.1055/a-0746-4288. Epub 2018 Sep 21. No abstract available.

PMID:
30241106
4.

[Pitfalls in the Diagnosis of Diabetes: Are we too Lax with Laboratory Parameters?]

Landgraf R, Nauck M, Freckmann G, Müller UA, Heinemann L, Kellerer M, Müller-Wieland D.

Dtsch Med Wochenschr. 2018 Oct;143(21):1549-1555. doi: 10.1055/a-0673-2156. Epub 2018 Sep 20. German.

5.

Higher HbA1c Measurement Quality Standards are Needed for Follow-Up and Diagnosis: Experience and Analyses from Germany.

Heinemann L, Kaiser P, Freckmann G, Grote-Koska D, Kerner W, Landgraf R, Merker L, Müller UA, Müller-Wieland D, Roth J, Spannagl M, Wallaschofski H, Nauck M.

Horm Metab Res. 2018 Oct;50(10):728-734. doi: 10.1055/a-0721-2273. Epub 2018 Sep 14.

PMID:
30216941
6.

[Cardiovascular risk in gout patients : Cardiovascular Safety of Febuxostat or Allopurinol in Participants with Gout and Cardiovascular Comorbidities (CARES)].

Müller-Wieland D, Nitschmann S.

Internist (Berl). 2018 Sep 3. doi: 10.1007/s00108-018-0486-2. [Epub ahead of print] Review. German. No abstract available.

PMID:
30178096
7.

Definition, Classification and Diagnosis of Diabetes Mellitus.

Petersmann A, Nauck M, Müller-Wieland D, Kerner W, Müller UA, Landgraf R, Freckmann G, Heinemann L.

Exp Clin Endocrinol Diabetes. 2018 Jul;126(7):406-410. doi: 10.1055/a-0584-6223. Epub 2018 Jul 5.

PMID:
29975979
8.

Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes.

Müller-Wieland D, Kellerer M, Cypryk K, Skripova D, Rohwedder K, Johnsson E, Garcia-Sanchez R, Kurlyandskaya R, Sjöström CD, Jacob S, Seufert J, Dronamraju N, Csomós K.

Diabetes Obes Metab. 2018 Nov;20(11):2598-2607. doi: 10.1111/dom.13437. Epub 2018 Jul 16.

PMID:
29947099
9.

Inactivation of SREBP-1a Phosphorylation Prevents Fatty Liver Disease in Mice: Identification of Related Signaling Pathways by Gene Expression Profiles in Liver and Proteomes of Peroxisomes.

Knebel B, Hartwig S, Jacob S, Kettel U, Schiller M, Passlack W, Koellmer C, Lehr S, Müller-Wieland D, Kotzka J.

Int J Mol Sci. 2018 Mar 25;19(4). pii: E980. doi: 10.3390/ijms19040980.

10.

Impact of Autoimmune Thyroiditis on Reproductive and Metabolic Parameters in Patients with Polycystic Ovary Syndrome.

Ulrich J, Goerges J, Keck C, Müller-Wieland D, Diederich S, Janssen OE.

Exp Clin Endocrinol Diabetes. 2018 Apr;126(4):198-204. doi: 10.1055/s-0043-110480. Epub 2018 Mar 5.

PMID:
29506313
11.

Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials.

Henry RR, Müller-Wieland D, Taub PR, Bujas-Bobanovic M, Louie MJ, Letierce A, Ginsberg HN.

Diabetes Obes Metab. 2018 Jul;20(7):1632-1641. doi: 10.1111/dom.13273. Epub 2018 Mar 25.

12.

[Type 2 Diabetes Diabetes in Older Adults: Example for Patient-Centered Drug Therapy].

Müller-Wieland D.

Dtsch Med Wochenschr. 2018 Feb;143(4):253-261. doi: 10.1055/s-0043-106792. Epub 2018 Feb 22. German.

PMID:
29471574
13.

Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial.

Ray KK, Leiter LA, Müller-Wieland D, Cariou B, Colhoun HM, Henry RR, Tinahones FJ, Bujas-Bobanovic M, Domenger C, Letierce A, Samuel R, Del Prato S.

Diabetes Obes Metab. 2018 Jun;20(6):1479-1489. doi: 10.1111/dom.13257. Epub 2018 Mar 23.

14.

Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial.

Leiter LA, Cariou B, Müller-Wieland D, Colhoun HM, Del Prato S, Tinahones FJ, Ray KK, Bujas-Bobanovic M, Domenger C, Mandel J, Samuel R, Henry RR.

Diabetes Obes Metab. 2017 Dec;19(12):1781-1792. doi: 10.1111/dom.13114. Epub 2017 Oct 10.

15.

Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials.

Leiter LA, Müller-Wieland D, Baccara-Dinet MT, Letierce A, Samuel R, Cariou B.

Diabet Med. 2018 Jan;35(1):121-130. doi: 10.1111/dme.13450. Epub 2017 Aug 31.

16.

Design and rationale of the ODYSSEY DM-DYSLIPIDEMIA trial: lipid-lowering efficacy and safety of alirocumab in individuals with type 2 diabetes and mixed dyslipidaemia at high cardiovascular risk.

Müller-Wieland D, Leiter LA, Cariou B, Letierce A, Colhoun HM, Del Prato S, Henry RR, Tinahones FJ, Aurand L, Maroni J, Ray KK, Bujas-Bobanovic M.

Cardiovasc Diabetol. 2017 May 25;16(1):70. doi: 10.1186/s12933-017-0552-4.

17.

Mechanisms of Insulin Resistance in Primary and Secondary Nonalcoholic Fatty Liver.

Jelenik T, Kaul K, Séquaris G, Flögel U, Phielix E, Kotzka J, Knebel B, Fahlbusch P, Hörbelt T, Lehr S, Reinbeck AL, Müller-Wieland D, Esposito I, Shulman GI, Szendroedi J, Roden M.

Diabetes. 2017 Aug;66(8):2241-2253. doi: 10.2337/db16-1147. Epub 2017 May 10.

18.

Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial.

Cariou B, Leiter LA, Müller-Wieland D, Bigot G, Colhoun HM, Del Prato S, Henry RR, Tinahones FJ, Letierce A, Aurand L, Maroni J, Ray KK, Bujas-Bobanovic M.

Diabetes Metab. 2017 Oct;43(5):453-459. doi: 10.1016/j.diabet.2017.01.004. Epub 2017 Mar 24.

19.

Can LDL cholesterol be too low? Possible risks of extremely low levels.

Olsson AG, Angelin B, Assmann G, Binder CJ, Björkhem I, Cedazo-Minguez A, Cohen J, von Eckardstein A, Farinaro E, Müller-Wieland D, Parhofer KG, Parini P, Rosenson RS, Starup-Linde J, Tikkanen MJ, Yvan-Charvet L.

J Intern Med. 2017 Jun;281(6):534-553. doi: 10.1111/joim.12614. Review.

PMID:
28295777
20.

[Diabetology as an interdisciplinary challenge].

Müller-Wieland D, Marx N.

Internist (Berl). 2017 Apr;58(4):329-335. doi: 10.1007/s00108-017-0204-5. Review. German.

PMID:
28233014

Supplemental Content

Loading ...
Support Center